LUNGevityKristin Posted May 7, 2020 Share Posted May 7, 2020 New Drug Approval Alert: FDA approves capmatinib (Tabrecta) for Met Exon 14 skipping NSCLC – a mutation seen in 3%-4% of #NSCLC. A companion diagnostic to identify these mutations has also been given the green light. The approval reinforces the need for more comprehensive biomarker testing to identify rare mutations and drive better outcomes. https://www.curetoday.com/articles/fda-approves-tabrecta-the-first-targeted-drug-for-patients-with-nonsmall-cell-lung-cancer-and-met-exon-14?fbclid=IwAR0p68saohJq8-94b4-4HXb4_DCbB-Yio8oRM8yxFX0HZ4BLzS2eSa_viYI Rower Michelle 1 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.